The Human Immunodeficiency Virus Type 1 (HIV 1) Market is estimated to be valued at USD 39.1 billion in 2025 and is projected to reach USD 70.1 billion by 2035, registering a compound annual growth rate (CAGR) of 6.0% over the forecast period.
-market-market-value-analysis.webp "Human Immunodeficiency Virus Type 1 (hiv 1) Market Market Value Analysis")
| Metric | Value |
|---|---|
| Human Immunodeficiency Virus Type 1 (HIV 1) Market Estimated Value in (2025 E) | USD 39.1 billion |
| Human Immunodeficiency Virus Type 1 (HIV 1) Market Forecast Value in (2035 F) | USD 70.1 billion |
| Forecast CAGR (2025 to 2035) | 6.0% |
The Human Immunodeficiency Virus Type 1 market is experiencing sustained growth driven by continuous advancements in antiretroviral therapies and increasing global efforts to manage and reduce HIV transmission. The rising prevalence of HIV infections in various regions has prompted healthcare providers and governments to prioritize effective treatment regimens.
The market is influenced by the development of drugs that offer improved efficacy, reduced side effects, and simplified dosing schedules, which enhance patient adherence. Innovations in combination therapies and personalized medicine are expanding treatment options and improving long-term outcomes.
The growing focus on early diagnosis and treatment initiation, supported by public health initiatives, is also contributing to increased market demand. Future growth opportunities are expected to emerge from expanding access in developing countries, ongoing research on novel drug classes, and integration of digital health tools to support patient management.
The market is segmented by Drug Class and region. By Drug Class, the market is divided into Integrase Inhibitors, Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Entry and Fusion Inhibitors, Protease Inhibitors, and Coreceptor Antagonists. Regionally, the market is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.
-market-analysis-by-drug-class.webp "Human Immunodeficiency Virus Type 1 (hiv 1) Market Analysis By Drug Class")
When segmented by drug class, integrase inhibitors are projected to hold 35.7% of the total market revenue in 2025, making them the leading drug class segment. This leadership has been driven by their superior efficacy in suppressing viral replication and a favorable safety profile compared to earlier antiretroviral classes.
The convenience of once-daily dosing and lower risk of drug resistance have further supported their adoption by clinicians. Clinical data and treatment guidelines increasingly recommend integrase inhibitors as first-line therapy, reinforcing their market position.
Additionally, pharmaceutical companies have invested significantly in developing fixed-dose combinations including integrase inhibitors, which improve patient compliance and simplify treatment regimens. The growing preference for integrase inhibitors reflects their ability to meet both clinical needs and patient lifestyle considerations, solidifying their dominance within the HIV 1 treatment landscape.
The global population of individuals infected with this virus rapidly increased during the historical period. As a result of the lack of sufficient diagnosis and treatment infrastructure, the disease has heavily impacted poor and developing countries on a wide scale. From 2020 to 2025, sales witnessed significant growth, registering a CAGR of 1.6%.
The incidence of HIV is soaring at an alarming rate. Based on the World Health Organization (WHO), a guesstimated 33.0 million people are infected with HIV. This has resulted in higher public awareness, which is leading to a rise in test methods. Over the forecast period, this will result in an increase in demand for HIV medicines with higher efficacy for the treatment and care of the disease.
Burgeoning HIV/AIDS Incidence to Push Market Growth
One of the key contributing factors expected to propel market growth is the rising prevalence of HIV/AIDS, particularly in Africa. According to the World Health Organization (WHO), an estimated 36.9.0 million people were living with HIV infection in 2024, with 1.5 million [1.1 million-2.0 million] new HIV infections.
According to WHO, women and girls constituted 54% of all HIV-positive people. This large patient population in various regions is driving up demand for antiretroviral (ARV) drugs. Furthermore, the government is working to improve HIV-1 patients' access to treatment and assessment. This is expected to fuel the global HIV-1 market.
Combined efforts of the government and several NGOs to propel the market growth
The deliberate initiatives of the government and multiple NGOs to supply at-risk individuals with better exposure to disease diagnosis and treatment for infected patients are key factors driving the HIV-1 market growth.
Numerous companies, including Cipla, Inc. and Gilead Sciences, Inc., have also implemented diagnosis education programs to lessen the detrimental ramifications of infectious diseases. The potential growth of this market is heavily reliant on the unfulfilled assessment and treatment needs in African and Asian countries.
Scarcity of Treatment Access and Lack of awareness of HIV Infection Status May Stifle Growth
Despite advances in technology development, enhanced scientific knowledge of HIV, and the affordability of therapeutic approaches, some detaining aspects are reducing future growth. Many individuals who are HIV-positive or at risk of becoming HIV-positive are unable to get timely treatment access. Besides that, there is no treatment for this virus.
As reported by the Joint United Nations Program on HIV/AIDS (UNAIDS), for instance, diagnosis metrics are distributed unevenly around the world. The lack of sufficient treatment options continues to be a challenge in middle-income and emerging nations, stifling the expansion of the HIV1 market.
-market-cagr-analysis-by-country.webp "Human Immunodeficiency Virus Type 1 (hiv 1) Market Cagr Analysis By Country")
North America's dominance is due to the high prevalence of HIV infection
With a market share of USD 39.1 Billion in 2025, North America dominated the market. This region's dominance is credited to the rising incidence of HIV infection in the US citizenry. Based on a study performed by the Centers for Disease Control (CDC) in 2039.1, an estimated 29.2 million people were living with HIV at the end of 2020.
With such a large patient population, the requirement for HIV drugs skyrockets. The population's consciousness is another aspect that contributes to regional growth. Furthermore, the presence of prominent players providing new HIV medications for the treatment of HIV1 transmission would augment the market growth.
Because of its dense population, the Asia Pacific market is the fastest-growing region
Owing to the highly populous nations, like China and India, with a huge proportion of HIV patients, the Asia Pacific market is predicted to be the fastest-growing market with the largest CAGR over the forecast period. Moreover, the vast number of therapeutic interventions and financial support from the private sector and medical companies are expected to propel the industry.
For example, Gilead Sciences, Inc., one of the world's biggest antiretroviral drug manufacturers, declared a USD 36.9 Million funding for its 'Gilead Asia Pacific Rainbow Grant Program' in Asia Pacific in December 2024. The program consists of Gilead's initiative to strengthen public-private collaborations in the Asia Pacific region in order to tackle the difficulties posed by HIV-infected patients.
Integrase inhibitors are preferred as first-line treatments for recently diagnosed patients
As the primary line of treatment for HIV, the integrase inhibitors segment held the second-highest market share in 2024, supporting the growth of the segment. Integrase inhibitors are advised as initial treatments for newly diagnosed HIV infection by the International AIDS Society (IAS).
The non-nucleoside reverse transcriptase inhibitors (NRTIs) segment has the smallest share of the market due to significantly fewer requirements for this drug class compared to the late innovative pharmaceutical launches
-market-analysis-by-company.webp "Human Immunodeficiency Virus Type 1 (hiv 1) Market Analysis By Company")
Key players in the Human Immunodeficiency Virus Type 1 (HIV 1) market are AbbVie, Inc, Boehringer, and Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc, Genentech, Inc, Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2025) | USD 39.1 billion |
| Anticipated Forecast Value (2035) | USD 70.1 billion |
| Projected Growth Rate (2025 to 2035) | 6% CAGR |
| Base Year for Estimation | 2025 |
| Historical Data | 2020 to 2025 |
| Forecast Period | 2025 to 2035 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2025 to 2035 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Mexico, Germany, UK, France, Spain, Italy, Russia, China, Japan, India, South Korea, Australia, Saudi Arabia, South Africa, UAE, Israel |
| Key Companies Profiled | AbbVie Inc.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Cipla Inc.; Genentech Inc.; Gilead Sciences, Inc.; Merck & Co. Inc.; ViiV Healthcare; GlaxoSmithKline; Sanofi |
| Customization | Available Upon Request |
The global human immunodeficiency virus type 1 (HIV 1) market is estimated to be valued at USD 39.1 billion in 2025.
The market size for the human immunodeficiency virus type 1 (HIV 1) market is projected to reach USD 70.1 billion by 2035.
The human immunodeficiency virus type 1 (HIV 1) market is expected to grow at a 6.0% CAGR between 2025 and 2035.
The key product types in human immunodeficiency virus type 1 (HIV 1) market are integrase inhibitors, nucleoside-analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, protease inhibitors and coreceptor antagonists.
In terms of , segment to command 0.0% share in the human immunodeficiency virus type 1 (HIV 1) market in 2025.
Explore Similar Insights
Human Immunodeficiency Virus Type 1 (HIV 1) Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
